Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells
- 186 Downloads
It is estimated that one in eight women will be affected with cancer during their lives, which means over 1 million women worldwide will be diagnosed with breast cancer in the year of 2011. Roughly, 70% of breast cancer will be estrogen receptor-alpha (ER-α) positive. The presence of ER-α is associated with better prognosis and is able to determine if tumors will respond to the estrogen-blocking/ER-antagonist drug Tamoxifen (TAM). However, a significant fraction of ER-positive tumors respond with minimal or no response to TAM. It is unclear why some breast cancer cells resist TAM and how to make these cells respond. Early evidence suggests Pomegranate fruit extracts (PFEs) exhibit an anticancer effect against some cancers. The objective of the study was to determine whether PFEs may able to enhance/sensitize the TAM’s effect in ER-positive MCF-7 breast cancer cells. To test the hypothesis, we determined the effect of PFEs on sensitive and TAM-resistant-MCF-7 cell viability and cell death in the presence or absence of TAM under estrogenic or non-estrogenic culture environment. The present studies demonstrated that PFEs enhance the TAM action in both sensitive and TAM-resistant MCF-7 cells through the inhibition of cell viability (regular or estrogen-induced) by inducing cell-death machinery. Collectively, the results showed for the first time that pomegranate combined with TAM may represent a novel and a powerful approach to enhance and sensitize TAM action.
KeywordsPomegranate Tamoxifen Estrogen receptor and breast cancer
We thank Drs. Snigdha Banerjee for excellent technical assistance, Dr. Peter Van Veldhuizen for critical reading and other CRU members for discussion. The work was supported by the VA Merit Review grants to SK and SKB and Midwest Biomedical Research Foundation for Summer Student stipend to SB.
- Bartow SA (1999) The breast. In: Rubin E, Farber JL (eds) Pathology. Lippincott-Raven, Philadelphia, pp 1029–1048Google Scholar
- Crowe DR, Lampejo OT (1996) Malignant tumor of the breast. In: Blackwell RE, Grotting JC (eds) Diagnosis and management of breast cancer. England, Blackwell Sciences, pp 103–134Google Scholar
- Hayes DF, Robertson JF (2002) Overview and concepts of endocrine therapy. In: Robertson JF, Nicholson RI, Hayes DF (eds) Endocrine therapy of breast cancer. Martin Dunitz Ltd, London, pp 3–10Google Scholar
- Ormerod MG (2004) Cell-cycle analysis of asynchronous populations. Methods Mol Biol 263:345–54Google Scholar
- Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A (2006a) Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12:4018–4026PubMedCrossRefGoogle Scholar
- Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685PubMedCrossRefGoogle Scholar
- Tavassoli FA (1999) Pathology of breast. McGraw-Hill, New YorkGoogle Scholar
- Tormey DC, Gray R, Falkson HC (1996) Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. East Coop Oncol Group J Natl Cancer Inst 88:1828–1833Google Scholar
- Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R, Takenoshita S (1999) Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res 5:2971–2977PubMedGoogle Scholar